Amit Pawale

Amit Pawale

Auto-generated profile, based on publicly available information

Amit Pawale

Division of Cardiothoracic Surgery Washington University School of Medicine in St. Louis St. Louis Missouri USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in JTCVS Open
Verified
Journal Article
Open access
SRSophia H. Roberts
Sophia H. Roberts
ESErin M. Schumer
Erin M. Schumer
MSMary Sullivan
Mary Sullivan
JGJohn Grotberg
John Grotberg
BJBianca Jenkins
Bianca Jenkins
APAmit Pawale
Amit Pawale
Open decannulation from femoral venoarterial extracorporeal membrane oxygenation (VA-ECMO) carries high risk of morbidity, including groin wound infection. This study evaluated the impact of percutaneous decannulation on rates of groin wound infection in patients decannulated from femoral VA-ECMO. Between January 1, 2022, and April 30, 2023, 47 consecutive patients received percutaneous femoral VA-ECMO and survived to decannulation. A percutaneous suture-mediated closure device was used for decannulation in patients with relatively smaller arterial cannulas. Patients with larger arterial cannulas or unsuccessful percutaneous closures underwent surgical cutdown and repair of the femoral artery. The primary outcome was arterial site wound infection following decannulation. Among the 47 patients who survived to decannulation from VA-ECMO, 21 underwent percutaneous decannulation and 27 underwent surgical cutdown. One patient underwent 2 VA-ECMO runs, one with percutaneous decannulation and one with surgical cutdown. Percutaneous decannulation was attempted in 22 patients, with 21 of 22 (95.5%) success rate. Decannulation procedure length was significantly shorter in the percutaneous group (79 minutes vs 148 minutes, P = .0001). The percutaneous group had significantly reduced rates of groin wound complications (0% vs 40.7%, P = .001) and groin wound infections (0% vs 22.2%, P = .03) when compared with the surgical cutdown group. Three patients (14.3%) in the percutaneous group experienced vascular complications, including pseudoaneurysm at the distal perfusion catheter site and nonocclusive thrombus of the common femoral artery. Percutaneous decannulation may reduce decannulation procedure length and rate of groin wound infection in patients who survive to decannulation from VA-ECMO.

6 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
AKAli J. Khiabani
Ali J. Khiabani
APAmit Pawale
Amit Pawale

20 October 2023 in JTCVS Techniques
Verified
Journal Article
Open access
ESErin M. Schumer
Erin M. Schumer
YBYun Zhu Bai
Yun Zhu Bai
KKKunal D. Kotkar
Kunal D. Kotkar
MMM. Faraz Masood
M. Faraz Masood
AIAkinobu Itoh
Akinobu Itoh
APAmit Pawale
Amit Pawale
The Impella 5.5 (Abiomed, Inc), a surgically implanted endovascular microaxial left ventricular assist device, is increasingly used worldwide and there have been more than 10,000 implants. The purpose of this study is to describe a large-volume, single-center experience with the use of the Impella 5.5. Data were obtained retrospectively from patients supported with the Impella 5.5 implanted at our institution from May 1, 2020, to December 31, 2022. Demographic, operative, and postoperative outcomes for each group are described. Results are reported in median (interquartile range) or n (%). The entire cohort was divided into 5 main groups based on the intention to treat at the time of the Impella 5.5 implantation: (1) patients who had a planned Impella 5.5 implanted at the time of high-risk cardiac surgery; (2) patients with cardiogenic shock; (3) patients bridged to a durable left ventricular assist device; (4) patients bridged to transplant; and (5) patients with postcardiotomy shock who received an unplanned Impella 5.5 implant. A total of 126 patients were supported with the Impella 5.5. Overall survival to device explant was 76.2%, with 67.5% surviving to discharge. Midterm survival was assessed with a median follow-up time of 318 days and demonstrated an overall survival of 60.3% and a median of 650 days (549-752). Outcomes after using the Impella 5.5 are variable depending on the indication of use. Patient selection may be of utmost importance and requires further experience with this device to determine who will benefit from insertion.

13 November 2024 in US Cardiology Review
Verified
Journal Article
Open access
PDF file
PSPreet Shaikh
Preet Shaikh
MRMario Rodriguez Rivera
Mario Rodriguez Rivera
MBMichael A Beal
Michael A Beal
MSMatthew R Schill
Matthew R Schill
APAmit Pawale
Amit Pawale
JMJonathan D Moreno
Jonathan D Moreno
Learn more about the management of atrial myxoma with severe pulmonary hypertension in this free article from USC Journal. Left Atrial Myxoma.

25 July 2023 in JTCVS Techniques
Verified
Journal Article
Open access
ESErin M. Schumer
Erin M. Schumer
KKKunal D. Kotkar
Kunal D. Kotkar
MMM. Faraz Masood
M. Faraz Masood
TKTsuyoshi Kaneko
Tsuyoshi Kaneko
RDRalph J. Damiano
Ralph J. Damiano
APAmit Pawale
Amit Pawale
Even though severe tricuspid regurgitation is not uncommon after cardiac transplantation, primary severe tricuspid regurgitation is rare. We present such a case with additional complexities. The patient was 44-year-old man with a HeartWare durable left ventricular assist device (Heartware Inc) who received a temporary right ventricular assist device (RVAD) with a ProtekDuo cannula (LivaNova Inc USA) for refractory ventricular fibrillation and underwent a heart transplant as United Network for Organ Sharing Status 1, in the presence of partially compensated cardiogenic shock, renal failure. Given complex re-operative surgery in a volume-overloaded patient with unknown pulmonary vascular resistance, an RVAD cannula was preserved and re- inserted during cardiac transplant. Postoperatively he required hemodialysis, had severe primary tricuspid regurgitation discovered after RVAD removal and developed Enterobacter mediastinitis. He underwent complex tricuspid valve repair for flail tricuspid leaflet due to ruptured papillary muscle likely due to RVAD cannula injury, after multiple mediastinal washouts and was followed by delayed chest reconstruction. The patient is doing well, 6 months after discharge to home, asymptomatic, without re-admissions, on renal recovery path, with no tricuspid regurgitation and good biventricular function. Replacing the tricuspid valve in presence of hemodialysis catheter, immunosuppression and mediastinitis could be high risk for endocarditis. Even though we have short-term follow-up, tricuspid valve repair can be an effective way of managing primary severe regurgitation especially when there is a desire or need to avoid valve replacement.

1 September 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
JSJoel Schilling
Joel Schilling
APAmit Pawale
Amit Pawale